Afya (NASDAQ:AFYA) Stock Gets Price Target Reduction from JPMorgan Chase & Co.

Afya (NASDAQ:AFYA) had its price target decreased by JPMorgan Chase & Co. from $19.00 to $17.50 in a research report released on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other equities research analysts also recently weighed in on the company. Bradesco Corretora raised Afya to an “outperform” rating and set a $17.00 price objective on the stock in a report on Thursday, September 24th. Wall Street Zen lowered Afya from a “buy” rating to a “hold” rating in a research note on Saturday, October 31st. Bank of America raised Afya from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a report on Thursday, October 29th. Zacks Research upgraded Afya from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Weiss Ratings downgraded Afya from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, October 29th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $15.18.

Afya Price Performance

Shares of Afya stock opened at $10.15 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.20 and a current ratio of 2.20. The firm’s 50-day simple moving average is $13.32 and its 200-day simple moving average is $14.12. Afya has a twelve month low of $9.66 and a twelve month high of $16.16. The firm has a market cap of $951.29 million, a P/E ratio of 6.19, a price-to-earnings-growth ratio of 1.68 and a beta of 0.43.

Afya (NASDAQ:AFYA) last posted its earnings results on Friday, August 14th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. Afya had a net margin of 20.55% and a return on equity of 17.58%. The business had revenue of $187.80 million for the quarter, compared to analysts’ expectations of $189.62 million. As a group, research analysts expect that Afya will post 1.68 EPS for the current fiscal year.

Insider Buying and Selling at Afya

In other news, insider Santos Welder Ferreira sold 4,161 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $13.30, for a total value of $55,341.30. Following the sale, the insider owned 35,000 shares of the company’s stock, valued at approximately $465,500. This represents a 10.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.80% of the company’s stock.

Hedge Funds Weigh In On Afya

A hedge fund recently bought a new position in Afya stock. Engineers Gate Manager LP acquired a new position in shares of Afya Limited (NASDAQ:AFYA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,882 shares of the company’s stock, valued at approximately $325,000. 88.02% of the stock is owned by hedge funds and other institutional investors.

Afya Company Profile

Afya Limited is a medical education and digital health company focused on Brazil. Through its educational platform, the company provides undergraduate medical education, medical residency preparation, specialization and continuing medical education programs, and other learning resources for students and physicians.

Afya also offers digital products and services intended to support healthcare professionals throughout their careers. These include clinical content, study tools, telemedicine and practice-management solutions, and subscription-based applications designed to assist physicians with education, clinical decision-making, and patient care.

The company has expanded through the development and acquisition of medical schools, education businesses, and health technology platforms serving different stages of the medical professional lifecycle.